Doxorubicin toxicity: Histological and ultrastructural tissue damage
DOI:
https://doi.org/10.24193/subbbiol.2026.1.03Keywords:
doxorubicin, pharmacological toxicity, histopathology, ultrastructural analysisAbstract
Doxorubicin (DOX) is an effective chemotherapeutic with known toxic effects over the liver, kidneys and most importantly the heart. DOX effects, such as oxidative stress induction, topoisomerase II poisoning and activation of pro-inflammatory pathways are a double-edged sword. While enhancing the antitumoral activity of this agent, these mechanisms also contribute to tissue damage which limits its use. To build upon previous research that evaluated circulating biomarkers of DOX-induced cardiac toxicity, this study offers additional perspectives on structural effects on tissues along with a short literature review of DOX use.
Article history: Received 3 April 2025; Revised 1 April 2026;
Accepted 2 June 2026; Available online 25 June 2026.
References
Adebayo, M., Singh, S., Singh, A.P. & Dasgupta, S. (2021). Mitochondrial fusion and fission: the fine-tune balance for cellular homeostasis. FASEB J. 35(6), 321620. https://doi.org/10.1096/fj.202100067R
Al Hamid, A., Beckett, R., Wilson, M., Jalal, Z., Cheema, E., Al-Jumeily OBE, D., Coombs, T., Ralebitso-Senior, K. & Assi, S. (2024). Gender bias in diagnosis, prevention, and treatment of cardiovascular diseases: a systematic review. Cureus 16(2), e54264. https://doi.org/10.7759/cureus.54264
Anca, E., Sabău, F., Vădan, A., Marinescu, M., Licărete, E., Roșioru, C., Stoica, A.D., Dobre, C. & Banciu, M. (2024). Assessment of circulating biomarkers in a rat model of doxorubicin-induced cardiotoxicity. Stud. Univ. Babes Bolyai Biol. 69(2), 7–22. https://doi.org/10.24193/subbbiol.2024.2.01
Berg Gundersen, A.E., Sørlie, T. & Bergvik, S. (2017). Women with coronary heart disease – making sense of their symptoms and their experiences from interacting with their general practitioners. Health Psychol. Behav. Med. 5, 29–40. https://doi.org/10.1080/21642850.2016.1263574
Bonadonna, G. Monfardini, S. (1969). Cardiac toxicity of daunorubicin. Lancet 293(7599), 837-838. https://doi.org/10.1016/s0140-6736(69)92093-5
Bonnet, L., Alexandersson, I., Baboota, R.K., Kroon, T., Oscarsson, J., Smith, U. & Boucher, J. (2022). Cellular senescence in hepatocytes contributes to metabolic disturbances in NASH. Front. Endocrinol. (Lausanne) 13, 957616. https://doi.org/10.3389/fendo.2022.957616
Cassinelli, G. (2016). The roots of modern oncology: from discovery of new antitumor anthracyclines to their clinical use. Tumori 2016(3), 226-235. https://doi.org/10.5301/tj.5000507
Christidi, E. & Brunham, L.R. (2021). Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death. Dis. 12(4), 339. https://doi.org/10.1038/s41419-021-03614-x
Craciun, C. & Barbu-Tudoran, L. (2013). Identification of new structural elements within “porosomes” of the exocrine pancreas: a detailed study using high-resolution electron microscopy. Micron 44, 137-142. https://doi.org/10.1016/j.micron.2012.05.011
Ding, M., Shi, R., Cheng, S., Li, M., De, D., Liu, C., Gu, X., Li, J., Zhang, S., Jia, M., Fan, R., Pei, J. & Fu, F. (2022). Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch. Redox Biol. 52, 102311. https://doi.org/10.1016/j.redox.2022.102311
Ezekowitz, J.A., Savu, A., Welsh, R.C., McAlister, F.A., Goodman, S.G. & Kaul, P., (2020). Is there a sex gap in surviving an acute coronary syndrome or subsequent development of heart failure? Circulation 142(23), 2231-2239. https://doi.org/10.1161/CIRCULATIONAHA.120.048015
Fatani, A., Baothman, O., Shash, L., Abuaraki, H., Zeyadi, M., Hosawi, S., Altayb, H. & Abo-Golayel, M. (2022). Hepatoprotective effect of date palm fruit extract against doxorubicin intoxication in Wistar rats: in vivo and in silico studies. Asian Pac. J. Trop. Biomed. 12(8), 357-366. https://doi.org/10.4103/2221-1691.350184
Forman, H.J., Maiorino, M. & Ursini, F. (2010). Signaling functions of reactive oxygen species. Biochemistry. 49(5), 835-842. https://doi.org/10.1021/bi9020378
Gabizon, A.A., Gabizon-Peretz, S., Modaresahmadi, S. & La-Beck, N.M. (2025). Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective. BMJ Oncol. 4(1), e000573. https://doi.org/10.1136/bmjonc-2024-000573
Gedikli, E., Barış, V.Ö., Yersal, N., Dinçsoy, A.B., Müftüoğlu, S.F. & Erdem, A. (2023). Taurine protects doxorubicin-Induced hepatotoxicity via its membrane-stabilizing effect in rats. Life 13(10), 2031. https://doi.org/10.3390/life13102031
He, H., Wang, L., Qiao, Y., Zhou, Q., Li, H., Chen, S., Yin, D., Huang, Q. & He, M., (2020a). Doxorubicin induces endotheliotoxicity and mitochondrial dysfunction via ROS/eNOS/NO pathway. Front. Pharmacol. 10, 1531. https://doi.org/10.3389/fphar.2019.01531
He, Q., Wang, F., Ryan, T.D., Chalasani, M. & Redington, A.N. (2020b). Repeated remote ischemic conditioning reduces doxorubicin-induced cardiotoxicity. JACC CardioOncol. 2(1), 41-52. https://doi.org/10.1016/j.jaccao.2020.01.005
Helms, L., Guimera, A.E., Janeway, K.A. & Bailey, K.M. (2023). Innovations in cancer treatment of children. Pediatrics 152(6), e2020301539. https://doi.org/10.1542/peds.2023-061539
Hussain, M.A., Abogresha, N.M., Abdelkader, G., Hassan, R., Abdelaziz, E.Z. & Greish, S.M. (2021). Antioxidant and anti-inflammatory effects of crocin ameliorate doxorubicin-induced nephrotoxicity in rats. Oxid. Med. Cell Longev. 2021, 8841726. https://doi.org/10.1155/2021/8841726
Jones, I.C. & Dass, C.R. (2022). Doxorubicin-induced cardiotoxicity: causative factors and possible interventions. J. Phar. Pharmacol. 74(12), 167-1688. https://doi.org/10.1093/jpp/rgac063
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I. & Kontek, R. (2023). Doxorubicin—an agent with multiple mechanisms of anticancer activity. Cells 12(4), 659. https://doi.org/10.3390/cells12040659
Lee, J., Choi, M.K. & Song, I.S., (2023). Recent advances in doxorubicin formulation to enhance pharmacokinetics and tumor targeting. Pharmaceuticals 16(6), 802. https://doi.org/10.3390/ph16060802
Lee, S.F., Luque-Fernandez, M.A., Chen, Y.H., Catalano, P.J., Chiang, C.L., Wan, E.Y.F., Wong, I.C.K., Chen, M.H. & Ng, A.K. (2020). Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong Blood Adv. 4(20), 5107-5117. https://doi.org/10.1182/BLOODADVANCES.2020002737
Leung, A.W.Y., Amador, C., Wang, L.C., Mody, U. V. & Bally, M.B. (2019). What drives innovation: the canadian touch on liposomal therapeutics. Pharmaceutics 11(3), 124. https://doi.org/10.3390/pharmaceutics11030124
Levick, S.P., Soto-Pantoja, D.R., Bi, J., Hundley, W.G., Widiapradja, A., Manteufel, E.J., Bradshaw, T.W. & Meléndez, G.C. (2019). Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 receptor and direct effects on cardiac fibroblasts. Heart Lung Circ. 28(10), 1598-1605. https://doi.org/10.1016/j.hlc.2018.08.003
Li, X.R., Cheng, X.H., Zhang, G.N., Wang, X.X. & Huang, J.M. (2022). Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer. J. Ovarian Res. 15(1), 96. https://doi.org/10.1186/s13048-022-01029-6
Linders, A.N., Dias, I.B., López Fernández, T., Tocchetti, C.G., Bomer, N. & Van der Meer, P. (2024). A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging. npj Aging 10(1), 9. https://doi.org/10.1038/s41514-024-00135-7
Liu, Y., Chen, S., Wen, Z., Meng, J., Yang, Y., Zhang, Y., Wang, J. & Cao, X. (2024). Comparative pharmacokinetics of free doxorubicin and a liposomal formulation in cats following intravenous administration. Front. Vet. Sci. 11, 1353775. https://doi.org/10.3389/fvets.2024.1353775
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F. & Colotti, G. (2023). Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming. Mol Aspects Med. 93, 101205. https://doi.org/10.1016/j.mam.2023.101205
Pernas, L. & Scorrano, L. (2016). Mito-morphosis: mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function. Annu Rev Physiol. 78 505-531. https://doi.org/10.1146/annurev-physiol-021115-105011
Prasanna, P.L., Renu, K. & Valsala Gopalakrishnan, A. (2020). New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sci. 250, 117599. https://doi.org/10.1016/j.lfs.2020.117599
Rawat, P.S., Jaiswal, A., Khurana, A., Bhatti, J.S. & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed. Pharmacother. 2021, 111708. https://doi.org/10.1016/j.biopha.2021.111708
Shandilya, M., Sharma, S., Das, P.P. & Charak, S. (2020). Molecular-level understanding of the anticancer action mechanism of anthracyclines, in: Arnouk, H., Hassan, B.A.R. (Eds.), Advances in precision medicine oncology. IntechOpen, 9. https://doi.org/10.5772/intechopen.94180
Shi, S., Chen, Y., Luo, Z., Nie, G. & Dai, Y. (2023). Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell Commun. Signal. 21(1), 61. https://doi.org/10.1186/s12964-023-01077-5
Sliwa, K., van der Meer, P., Petrie, M.C., Frogoudaki, A., Johnson, M.R., Hilfiker-Kleiner, D., Hamdan, R., Jackson, A.M., Ibrahim, B., Mbakwem, A., Tschöpe, C., Regitz-Zagrosek, V., Omerovic, E., Roos-Hesselink, J., Gatzoulis, M., Tutarel, O., Price, S., Heymans, S., Coats, A.J.S., Müller, C., Chioncel, O., Thum, T., de Boer, R.A., Jankowska, E., Ponikowski, P., Lyon, A.R., Rosano, G., Seferovic, P.M. & Bauersachs, J. (2021). Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur. J. Heart Fail. 23(4), 527-540. https://doi.org/10.1002/ejhf.2133
Sozen, E. & Ozer, N.K. (2017). Impact of high cholesterol and endoplasmic reticulum stress on metabolic diseases: an updated mini-review. Redox Biol. 12, 456-461. https://doi.org/10.1016/j.redox.2017.02.025
Szalay, C.I., Erdélyi, K., Kökény, G., Lajtár, E., Godó, M., Révész, C., Kaucsár, T., Kiss, N., Sárközy, M., Csont, T., Krenács, T., Szénási, G., Pacher, P. & Hamar, P. (2015). Oxidative/nitrative stress and inflammation drive progression of doxorubicin-induced renal fibrosis in rats as revealed by comparing a normal and a fibrosis-resistant rat strain. PLoS One 10(6), e0127090. https://doi.org/10.1371/journal.pone.0127090
Timm, K.N., Ball, V., Miller, J.J., Savic, D., West, J.A., Griffin, J.L. & Tyler, D.J. (2022). Metabolic Effects of doxorubicin on the rat liver assessed with hyperpolarized MRI and metabolomics. Front. Physiol. 12, 782745. https://doi.org/10.3389/fphys.2021.782745
Townsend, N., Kazakiewicz, D., Lucy Wright, F., Timmis, A., Huculeci, R., Torbica, A., Gale, C.P., Achenbach, S., Weidinger, F. & Vardas, P. (2022). Epidemiology of cardiovascular disease in Europe. Nat. Rev. Cardiol. 19(2), 133-143. https://doi.org/10.1038/s41569-021-00607-3
van den Boogaard, W.M.C., Komninos, D.S.J. & Vermeij, W.P. (2022). Chemotherapy side-effects: not all DNA damage is equal. Cancers (Basel). 14(3), 627. https://doi.org/10.3390/cancers14030627
van der Zanden, S.Y., Qiao, X. & Neefjes, J. (2021). New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J. 288(21), 6095-6111. https://doi.org/10.1111/febs.15583
Vitale, R., Marzocco, S. & Popolo, A. (2024). Role of oxidative stress and inflammation in doxorubicin-induced cardiotoxicity: a brief account. Int. J. Mol. Sci. 25(13), 7477. https://doi.org/10.3390/ijms25137477
WHO (World Health Organization) (2023). World Health Organization model list of essential medicines – 23rd list, 2023, in: The selection and use of essential medicines 2023. web annex A. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
Xie, S., Sun, Y., Zhao, X., Xiao, Y., Zhou, F., Lin, L., Wang, W., Lin, B., Wang, Z., Fang, Z., Wang, L. & Zhang, Y. (2024). An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity. Front. Pharmacol. 15, 1406247. https://doi.org/10.3389/fphar.2024.1406247
Yang, F., Teves, S.S., Kemp, C.J. & Henikoff, S. (2014). Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys. Acta. Rev. Cancer 1845(1), 84-89. https://doi.org/10.1016/j.bbcan.2013.12.002
Zhou, L., Shen, H., Li, X. & Wang, H. (2022). Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease. Front. Immunol. 13, 951406. https://doi.org/10.3389/fimmu.2022.951406
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Studia Universitatis Babeş-Bolyai Biologia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This work is licensed under a 